SARS-Cov-2 treatment subsidiary

Israeli biotech Pepticom (reported here previously) has raised $2.6 million to establish a company that can treat SARS-Cov-2 and its mutations. It will implement AI technology to design, discover and develop novel peptide molecules.,7340,L-3897696,00.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *